[featured_image]
  • Version
  • Download
  • File Size 0.00 KB
  • File Count 1
  • Create Date May 16, 2024
  • Last Updated May 16, 2024

A retrospective multicentre audit of outcome among patients with Anaplastic Lymphoma Kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with Crizotinib (CRZ) in England

From BTOG 2017: by Kent Yip (Cambridge), Presentation of a multicentre study of outcomes amongst ALK +ve NSCLC patients treated with Crizotinib

Attached Files

FileAction
A retrospective multicentre audit of outcome among patients with Anaplastic Lymphoma Kinase (ALK) gDownload